Antileukemic activity and cellular metabolism of the aryl phosphate derivative of bromo-methoxy zidovudine (compound WHI-07)

Arzneimittel-Forschung/Drug Research

Volumn 55, Issue 1, 2005, Pages 50-65

  Uckun, Fatih M ^a,b   Tai, Hung Liang ^a   D'Cruz, Osmond J ^a,c  

^a PARKER HUGHES INSTITUTE   (United States)

^b Parker Hughes Cancer Center   (United States)

^c Paradigm Pharmaceuticals   (United States)

Author keywords

Antileukemic agent; CAS 213982 96 8; CAS 30516 87 1; WHI 07, antileukemic activity, cellular metabolism; Zidovudine, aryl phosphate derivative

Indexed keywords

NUCLEOSIDE TRIPHOSPHATE; WHI 07; ZIDOVUDINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CELL DIVISION; CELL FRACTIONATION; CELL FUSION; CELL METABOLISM; CELL PROLIFERATION; CLONOGENIC ASSAY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG DETOXIFICATION; DRUG METABOLISM; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMIA CELL LINE; LYMPHOMA; MULTIPLE MYELOMA; NONHUMAN; NUCLEIC ACID SYNTHESIS; PROTEIN DEPLETION; ZEBRA FISH;

EID: 12944324693     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296824     Document Type: Article

References (61)

1. Voliotis, D., Diehl, V., Challenges in treating hematologic malignancies. Semin. Oncol. 29, 30 (2002)
2. Miller, W. H., Jr., Waxman, S., Differentiation induction as a treatment for hematologic malignancies. Oncogene 21, 3496 (2002)
3. Chauhan, D., Anderson, K. C., Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications. Apoptosis 8, 337 (2003)
4. Wang, Z.Y., Chen, Z., Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia. Lancet Oncol. 1, 101 (2000)
5. Maslak, P., Scheinberg, D., Targeted therapies for the myeloid leukaemias. Expert. Opin. Investig. Drugs 9, 1197 (2000)
6. Baumann, S., Krueger, A., Kirchhoff, S. et al., Regulation of T cell apoptosis during the immune response. Curr. Mol. Med. 2, 257 (2002)
7. Kitada, S., Pedersen, I. M., Schimmer, A. D., Reed, J. C., Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene 21, 3459 (2002)
8. Igney, F. H., Krammer, P. H., Death and anti-death: tumour resistance to apoptosis. Nature Rev. Cancer 2, 277 (2002)
9. Cortes, J. E., Kantarjian, H., Freireich, E. J., Acute lymphocytic leukemia: a comprehensive review with emphasis on biology and therapy. Cancer Treat. Res. 84, 291 (1996)
10. Silverman, L. B., Sallan, S. E., Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment. Curr. Opin. Hematol. 10, 290 (2003)
11. Schrappe, M., Beier R., Burger, B., New treatment strategies in childhood acute lymphoblastic leukaemia. Best Pract. Res. Clin. Haematol. 15, 729 (2002)
12. Child, J. A., Morgan, G. J., Davies, F. E. et al., High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. 348, 1875 (2003)
13. Heffner, L. T. Jr., Lonial, S., Breakthroughs in the management of multiple myeloma. Drugs 63, 1621 (2003)
14. Horwitz, J. R., Chua J., Noel, M., Nucleosides. V. The monomesylates of 1(2′-desoxy-beta-Dlyxofuranosyl)thymidine. J. Org. Chem. 29, 2076 (1964)
15. Multani, A. S., Furlong, C., Pathak, S. Reduction of telomeric signals in murine melanoma and human breast cancer cell lines treated with 3′-azido-2′-3′-dideoxythymidine. Int. J. Oncol. 13, 923 (1998)
16. Wagner, C. R., Ballato, G., Akanni, A. O. et al., Potent growth inhibitory activity of zidovudine on cultured human breast cancer cells and rat mammary tumors. Cancer Res. 57, 2341 (1997)
17. Balzarini, J., Pauwels, R., Baba, M. et al., The in vitro and in vivo antiretrovirus activity, and intracellular metabolism of 3′-azido- 2′,3′-dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on the cell species. Biochem. Pharmacol. 37, 897 (1988)
18. Wagner, C. R., Iyer, V. V., McIntee, E. J. Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides. Med. Res. Rev. 20, 417 (2000)
19. D'Cruz, O. J., Venkatachalam, T. K., Zhu, Z. et al., Aryl phosphate derivatives of bromo-methoxy azidothymidine are dual-function spermicides with potent anti-HIV activity. Biol. Reprod. 59, 503 (1998)
20. D'Cruz, O. J., Venkatachalam, T. K., Uckun, F. M., Structural requirements for potent spermicidal activity of dual-function aryl phosphate derivative of bromo-methoxy zidovudine (Compound WHI-07). Biol. Reprod. 62, 37 (2000)
21. D'Cruz, O. J., Shih, M-J., Yiv, S. H. et al., Synthesis, characterization and preclinical formulation of a dual-action phenyl phosphate derivative of bromo-methoxy zidovudine (compound WHI-07) with potent anti-HIV and spermicidal activities. Mol. Hum. Reprod. 5, 421 (1999)
22. D'Cruz, O. J., Venkatachalam T. K., Uckun, F. M., Thymidine kinase-independent intracellular delivery of bioactive nucleotides by aryl phosphate derivatives of bromo-methoxy zidovudine (compounds WHI-05 and WHI-07) in normal human female genital tract epithelial cells and sperm. Biol. Reprod. 64, 51 (2001)
23. D'Cruz, O. J., Dong, Y., Uckun, F. M., Apoptosis-inducing oxovanadium(IV) complexes of 1,10-phenanthroline against human ovarian cancer. Anticancer Drugs 11, 849 (2000)
24. Narla, R. K., Dong, Y., D'Cruz, O. J. et al., Bis(4,7-dimethyl-1,10- phenanthroline) sulfatooxovanadium(IV) as a novel apoptosis-inducing anticancer agent. Clin. Cancer Res. 6, 1546 (2000)
25. nd ed. University of Oregon Press, Eugene, OR (1993)
26. Benyumov, A. O., Dubrovskaya, T. A., Barmintsev, V A. et al., Duration of first mitotic cycles and staging of embryogenesis in Danio rerio. Rus. J. Dev. Biol. 26, 132 (1995)
27. Kimmel, C. B., Ballard, W. W., Kimmel, S. R. et al., Stages of embryonic development of the zebrafish. Dev. Dynam. 203, 253 (1995)
28. Navara, C. S., Benyumov, A., Vassilev, A. et al., Vanadocenes as potent anti-proliferative agents disrupting mitotic spindle formation in cancer cells. Anticancer Drugs 12, 369 (2001)
29. Tietze, F., Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione. Anal. Biochem. 27, 502 (1969)
30. Balzarini, J., Egberink, H., Hartmann, K. et al., Antiretrovirus specificity and intracellular metabolism of 2′, 3′-didehydro- 2′,3′-dideoxythymidine (Stavudine) and its 5′-monophosphate triester prodrug So324. Mol. Pharmacol. 50, 1207 (1996)
31. Balzarini, J., Karlsson, A., Aquaro, S. et al., Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives. Proc. Natl. Acad. Sci. USA 93, 7295 (1996)
32. Lee, J.-S., Paull, K., Alvarez, M. et al. et al., Rhodamine efflux patterns predict P-glycoprotein substrates in National Cancer Institute drug screen. Mol. Pharmacol. 46, 627 (1994)
33. Paietta, E., Andersen, J., Racevskis, J. et al., Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia 8, 968 (1994)
34. Williams, F. M., Clinical significance of esterases in man. Clin. Pharmacokinet. 10, 392 (1985)
35. Gaustad, R., Johnsen, H., Fonnum, F., Carboxylesterases in guinea pig. A comparison of the different isoenzymes with regard to inhibition by organophosphorus compounds in vivo and in vitro. Biochem. Pharmacol. 42, 1335 (1991)
36. Kaliste-Korhonen, E., Tuovinen, K., Hanninen, O., Interspecies differences in enzymes reacting with organophosphates and their inhibition by paraoxon in vitro. Hum. Exp. Toxicol. 15, 972 (1996)
37. Ehrich, M., Correll, L., Inhibition of carboxylesterases in SH-SY5Y human and NB41A3 mouse neuroblastoma cells by organophosphorus esters. J. Toxicol. Environ. Health 53, 385 (1998)
38. Morgan, E. W., Yan, B., Greenway, D. et al., Purification and characterization of two rat liver microsomal carboxylesterases (hydrolase A and B). Arch. Biochem. Biophys. 315, 495 (1994)
39. Decosterd, L. A., Cottin, E., Chen, X. et al., Simultaneous determination of deoxyribonucleoside in the presence of ribonucleoside triphosphates in human carcinoma cells by high-performance liquid chromatography. Anal. Biochem. 270, 59 (1999)
40. Sangeetha, P., Das, U. N., Koratkar, R. et al., Increase in free radical generation and lipid peroxidation following chemotherapy in patients with cancer. Free Radic. Biol. Med. 8, 15 (1990)
41. Meister, A., Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol. Ther. 51, 155 (1991)
42. Griffith, O. W., Meister, A., Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J. Biol. Chem. 254, 7558 (1979)
43. Radel, S., Fredericks, W., Mayhew, E. et al., P-glycoprotein expression and modulation of cell-membrane morphology in adriamycin-resistant P388 leukemia cells. Cancer Chemother. Pharmacol. 25, 241 (1990)
44. Fairchild, C. R., Ivy, S. P., Kao-Shan, C.-S. et al., Isolation of amplified and overexpressed DNA sequences from Adriamycin-resistant human breast cancer cells. Cancer Res. 47, 5141 (1987)
45. McGrath, T., Latoud, C., Arnold, S. T. et al., Mechanisms of multidrug resistance in HL60 cells. Biochem. Pharmacol. 38, 3611 (1989)
46. Krishnamachary, N., Ma, L., Zheng, L. et al., Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin. Oncol. Res. 6, 119 (1994)
47. Gottesman, M. M., Pastan, I., Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385 (1993)
48. Salmon, S. E., Dalton, W. S., Gorgan, T. M., Multidrug-resistant myeloma: Laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78, 44 (1991)
49. Kavallaris, M., The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance. Anticancer Drugs 8, 17 (1997)
50. McCracken, N. W., Blain, P. G., Williams, F. M., Human xenobiotic metabolizing esterases in liver and blood. Biochem. Pharmacol. 46, 1125 (1993)
51. Hall, I. H., Wong, O. T., Hall, E. S. et al., The cytotoxicity of N-substituted indazolones in murine and human tumor cells. Anticancer Drugs 4, 389 (1993)
52. Hall, I. H., Izydore, R., Hall, E. S. et al., The antineoplastic and cytotoxicity of benzohydroxamic acids and related derivatives in murine and human tumor cells. Anticancer Drugs 3, 273 (1992)
53. Zilfou, J. T., Smith, C.D., Differential interaction of cytochalasins with P-glycoprotein. Oncol. Res. 7, 435 (1995)
54. Dantzig, A. H., Shepard, R. L., Cao, J. et al., Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 56, 4171 (1996)
55. List, A., Non-P-glycoprotein drug export mechanisms of multidrug resistance. Sem. Hematol. 34, 20 (1997)
56. McIntee, E. J., Remmel, R. P., Schinazi, R. F. et al., Probing the mechanism of action and decomposition of amino acid phosphomonoester amidates of antiviral nucleoside prodrugs. J. Med. Chem. 40, 3323 (1997)
57. Valette, G., Pompon, A., Girardet, J. et al., Decomposition pathways and in vitro HIV inhibitory effects of IsoddA pronucleotides: toward a rational approach for intracellular delivery of nucleoside 5′-monophosphates. J. Med. Chem. 39, 1981 (1996)
58. Sipes, I. G., Gandolfi, A. J., Biotransformation of toxicants. In: Casarett and Doull's Toxicology, M.O. Amdur, J. Doull, C.D. Klaassen (eds.), 4th edition, pp. 89. Pergamon Press, New York (1991)
59. Kumar, R., Wang, L., Wiebe, L. I. et al., Synthesis, in vitro biological stability, and anti-HIV activity of 5-halo-6-alkoxy (ROR azido)-5,6,-dihydro- 3′-azido-3′-deoxythymidine diasteriomers as potential prodrugs to 3′-azido-3-deoxythymidine (AZT). J. Med. Chem. 37, 4297 (1994)
60. McGuigan, C., Canard, D., Sheeka, H. M. et al., Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite. J. Med. Chem. 39, 1748 (1996)
61. Venkatachalam, T. K., Tai, H-L., Vig, R. et al., Enhancing effects of a mono-bromo substitution at the para position of the phenyl moiety on the metabolism and anti-HIV activity of D4T-phenyl methoxyalaninyl phosphate derivatives. Bioorg. Med. Chem. Lett. 8, 3121 (1998)